WO1998026090A1 - Procede pour determiner la teneur en cholesterol des lipoproteines de haute densite - Google Patents
Procede pour determiner la teneur en cholesterol des lipoproteines de haute densite Download PDFInfo
- Publication number
- WO1998026090A1 WO1998026090A1 PCT/JP1997/004442 JP9704442W WO9826090A1 WO 1998026090 A1 WO1998026090 A1 WO 1998026090A1 JP 9704442 W JP9704442 W JP 9704442W WO 9826090 A1 WO9826090 A1 WO 9826090A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cholesterol
- hdl
- density lipoprotein
- surfactant
- lipoproteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/824—Immunological separation techniques
Definitions
- the present invention relates to a method for quantifying cholesterol in high-density lipoprotein (hereinafter, sometimes referred to as “HD LJ”).
- HD LJ high-density lipoprotein
- HDL which receives cholesterol from tissues including the atherosclerotic wall, is related to the action of removing cholesterol accumulated in cells, and is a risk preventive factor for various arteriosclerosis including coronary atherosclerosis. Levels are known to be useful guidelines for predicting the onset of atherosclerotic disease.
- Methods for measuring cholesterol in HDL include, for example, separating HDL from other lipoproteins by ultracentrifugation, and then subjecting it to cholesterol measurement. Methods for measuring are known. However, these methods have problems such as complicated operation and inability to process a large number of samples, and are hardly used on a daily basis.
- a commonly used method of measuring cholesterol in HDL in the field of clinical testing is to add a precipitant to a sample to aggregate lipoproteins other than HDL, remove this by centrifugation, and remove only the separated HDL.
- This is a method for measuring cholesterol in a supernatant containing
- this method is simpler than ultracentrifugation or electrophoresis, it is not satisfactory because it involves the operation of adding a precipitant and separating it. Need.
- Another method is to carry out an enzyme reaction in the presence of a bile salt or a nonionic surfactant (Japanese Patent Application Laid-Open No. 63-128498), and more recently, cholesterol esterase ⁇ cholesterol oxidase enzyme.
- a bile salt or a nonionic surfactant Japanese Patent Application Laid-Open No. 63-128498
- cholesterol esterase ⁇ cholesterol oxidase enzyme To chemically capture cholesterol in HDL in the presence of an inclusion compound such as cyclodextrin (Japanese Patent Laid-Open No. 7-301636) or to form an aggregate or complex with lipoproteins other than HDL.
- an inclusion compound such as cyclodextrin
- a method of capturing cholesterol in HDL by an enzymatic reaction Japanese Patent Application Laid-Open Nos. 8-131197 and 8-201393
- all of them are part of clinical samples.
- there is a problem with the specificity for example, discrepancies with the
- An object of the present invention is to provide a lipoprotein containing HDL and other lipoproteins such as low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), and chylomicron (CM) without requiring complicated fractionation and separation operations.
- An object of the present invention is to provide a method for quantitatively determining HDL cholesterol in HDL, which can selectively, simply and accurately quantify HDL cholesterol in a test sample.
- the present inventors have conducted intensive studies and found that some surfactants act on HDL but hardly act on other lipoproteins. Then, first, after cholesterol in lipoproteins other than high-density lipoprotein in the test sample is selectively eliminated, cholesterol derived from HDL is enzymatically quantified in the presence of the above-mentioned surfactant, thereby obtaining HDL. The present inventors have found that HDL cholesterol in a test sample containing lipoprotein and other lipoproteins can be selectively and simply and accurately quantified, and completed the present invention.
- the present invention provides a first step of selectively eliminating cholesterol in lipoproteins other than high-density lipoprotein in a test sample, and then, a product specific to high-density lipoprotein in the first step. And a second step of enzymatically quantifying cholesterol in the high-density lipoprotein by adding a surfactant that acts chemically, and a method for quantifying cholesterol in the high-density lipoprotein.
- HDL in a test sample containing other lipoproteins such as VLDL and CM can be selectively, simply and accurately quantified.
- FIG. 1 is a correlation diagram showing the relationship between the amount of cholesterol in HDL measured by the method of one example of the present invention and the amount of cholesterol in HDL measured by a conventional precipitation method.
- FIG. 2 is a correlation diagram showing the relationship between the amount of cholesterol in HDL measured by the method of another example of the present invention and the amount of cholesterol in HDL measured by a conventional precipitation method.
- FIG. 3 is a correlation diagram showing the relationship between the amount of cholesterol in HDL measured by the method of still another embodiment of the present invention and the amount of cholesterol in HDL measured by a conventional precipitation method.
- Cholesterol contained in lipoprotein includes ester cholesterol (cholesterol ester) and free cholesterol.
- the term “cholesterol” includes both of these.
- test sample used in the method of the present invention may be any sample that may contain lipoproteins such as HDL, LDL, 1_01_ and ⁇ M.
- lipoproteins such as HDL, LDL, 1_01_ and ⁇ M.
- body fluids such as serum And dilutions thereof, but are not limited thereto.
- the first step of the method of the present invention cholesterol in lipoproteins other than HDL in the test sample is selectively eliminated.
- “elimination” means decomposing cholesterol and preventing the decomposed product from being detected in the next second step.
- lipoproteins other than HDL that is, cholesterol contained in LDL, VLDL, CM and the like.
- cholesterol esterase and cholesterol oxidase act on the test sample in the absence of a surfactant that acts on HDL.
- a surfactant that acts on HDL.
- Ester cholesterol in lipoproteins is hydrolyzed by the action of cholesterol esterase to produce free cholesterol and fatty acids.
- the resulting free cholesterol and the free cholesterol originally present in the lipoprotein are oxidized by the action of cholesterol oxidase to produce cholesterone and hydrogen peroxide. The generated hydrogen peroxide is removed.
- Examples of the method for removing hydrogen peroxide include a method in which catalase is used to decompose water and oxygen, and a method in which peroxidase is used to remove D AOS (
- Examples include, but are not limited to:
- the first step is performed in the absence of a surfactant that acts on HDL, cholesterol in HDL hardly reacts and cholesterol in other lipoproteins such as LDL, VLDL, and CM Reacts and is erased. Thereby, cholesterol in HDL is selectively quantified in the next second step.
- the concentration of cholesterol esterase in the reaction solution of the first step is preferably about 0.2 to 1.0 U Zml, and the concentration of cholesterol oxidase is preferably about 0.1 to 0.7 U unit I. Further, the concentration of catalase is preferably about 40 to 100 UZmI, and the concentration of peroxidase is preferably about 0.4 to 1.0 UI. Further, the concentration of the compound which produces colorless quinone by reacting with hydrogen peroxide is preferably about 0.4 to 0.8 mmo I / 1.
- the reaction in the first step is preferably performed in a buffer having a pH of 5 to 8, and the buffer is preferably a buffer of phosphate, glycine, tris, and good.
- good buffers such as Bis-ESris, PI PES, MO PSO, BES, HE PES and PO PSO are preferable, and the concentration of the buffer is preferably about 10 to 50 OmM.
- a divalent metal ion may be included in the reaction solution to further enhance elimination of lipoproteins other than HDL.
- the divalent metal ion copper ion, iron ion and magnesium ion can be preferably used. 4442
- the concentration of the divalent metal ion is preferably about 5 to 20 OmM.
- the reaction solution of the first step may optionally contain a lipoprotein hydrolase.
- the addition of this enzyme is preferred because cholesterol in VLDL particularly easily reacts.
- the concentration of this enzyme in the reaction solution is preferably about 5.0 to 10.0 U / ml.
- the reaction temperature in the first step is suitably from about 25 ° C to 40 ° C, most preferably 37 ° C.
- the reaction time may be about 2 to 10 minutes.
- a surfactant that specifically acts on HDL is added to the product of the first step, and cholesterol in the high-density lipoprotein is enzymatically quantified.
- the term “surfactant that specifically acts on HDL” means that cholesterol in HDL reacts when enzymes such as cholesterol esterase and cholesterol oxidase act in the presence of the surfactant. (Reaction rate 70% or more, preferably 90% or more), but cholesterol in lipoproteins other than HDL hardly reacts (reaction rate 30% or less, preferably 20% or less).
- surfactants include surfactants having a hydrophilic / lipophilic balance (H LB) of 13 to 14, and among them, nonionic surfactants having an H LB of 13 to 14
- Activators especially polyalkylene oxide derivatives
- the derivative herein include a higher alcohol condensate, a higher fatty acid condensate, a higher fatty acid amide condensate, a higher alkylamine condensate, a higher alkyl mercaptan condensate, and an alkylphenol condensate.
- a polyethylene oxide derivative is most preferable.
- HLB can be adjusted within the above range, and a mixture of such a plurality of surfactants can be used.
- the method for calculating the HLB of a surfactant is well known, and is described in, for example, "New Surfactant", written by Hiroshi Horiguchi, 1986, Sankyo Shuppan.
- preferable surfactants include polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene oleyl ether, and polyoxyethylene lauryl ether.
- examples thereof include, but are not limited to, polyoxyethylene higher alcohol (4 to 35 carbon atoms) ether, polyoxyethylene octylphenyl ether, polyoxyethylene nonylphenyl ether, and the like.
- the concentration of the surfactant in the second step is not particularly limited, but is preferably 0.05 to 3% by weight, and more preferably 0.1 to 1.5% by weight, based on the whole reaction mixture.
- HDL cholesterol in the test sample can be enzymatically quantified. That is, in the first step, most of the cholesterol in the lipoprotein other than the HDL is eliminated, but only the cholesterol in the HDL is quantified by a synergistic effect with the reaction in the second step.
- Enzymatic determination of cholesterol itself is well known in the art.
- hydrogen peroxide is generated from cholesterol ester and free cholesterol by the action of cholesterol esterase and cholesterol oxidase. Then, it can be carried out by quantifying the generated hydrogen peroxide.
- the quantitative determination of hydrogen peroxide is performed, for example, by reacting with a compound that reacts with hydrogen peroxide to form a quinone dye in the presence of peroxidase, and measuring the amount of the resulting quinone dye by absorbance measurement or the like. Can be.
- the quinone dye is formed, for example, by reacting hydrogen peroxide with 4-aminoaminopyrine and DAOS or HDAOS (N- (2-hydroxysulfopropyl) -13,5-dimethoxyaniline). You.
- the quinone dye thus formed has a maximum absorption at a wavelength of 593 nm when DAOS is used, and has a maximum absorption at a wavelength of 583 ⁇ m when HDAOS is used.
- the concentration of the compound that forms the quinone dye is not particularly limited, but for example, 41-aminoantipyrine is preferable (0.1 to 2.OmM, and more preferable is 0.5) based on the entire reaction mixture.
- reaction temperature, reaction time, buffer, pH are the same as the preferred reaction conditions for the first step. Is the same.
- catalase inhibitor such as sodium azide is used.
- Emulgen 911 polyoxyethylene nonyl ether, HLB 13.7
- Emulgen B Cholesterol in each lipoprotein enzymatically in the presence of 66 (polyoxyethylene derivative, HLB 13.2), or a mixture of Emulgen B 66 and Emulgen A 90 (polyoxyethylene derivative, HLB 14.5) Quantified. This operation was specifically performed as follows.
- the reaction rate of cholesterol (the proportion of cholesterol determined in cholesterol) was about 95% for cholesterol in HDL and about 18 to 22% for cholesterol in other lipoproteins.
- Emulgen 911 corresponds to the “surfactant that specifically acts on high-density lipoprotein” in the present invention.
- Emulgen B66 corresponds to the “surfactant that specifically acts on high-density lipoprotein” in the present invention.
- the hydrogen peroxide generated in the first step is decomposed by catalase, while the hydrogen peroxide generated in the second step reacts with HDAOS and 4-aminoantipyrine to form a quinone dye.
- the results are shown in Table 1 below.
- cholesterol in HDL is mostly It is quantitatively determined, but little or no cholesterol in the other lipoproteins is determined, indicating that the cholesterol in HDL can be selectively quantified by the method of the present invention.
- HDL cholesterol in the test sample was quantified in the same manner as in Example 1 except that healthy human serum was used as the test sample.
- HDL cholesterol in the same test sample was quantified by the precipitation method described in “Clinical tests”, 23, 121 (1979).
- FIG. 1 shows a correlation diagram of the obtained measurement results.
- Example 2 The same operation as in Example 1 was performed, except that the first reagent and the second reagent having the following compositions were used.
- cholesterol in HDL was mostly quantified, but little or no cholesterol in other lipoproteins was quantified. This shows that cholesterol in HDL can be selectively quantified.
- HDL cholesterol in the test sample was quantified in the same manner as in Example 3, except that healthy human serum was used as the test sample.
- HDL cholesterol in the same test sample was quantified by the precipitation method.
- Fig. 2 shows a correlation diagram of the obtained measurement results.
- the hydrogen peroxide produced in the first step is decomposed by catalase, while the hydrogen peroxide produced in the second step reacts with HDAOS and 4-aminoantipyrine to produce a quinone dye.
- the results are shown in Table 3 below.
- cholesterol in HDL was mostly quantified, but cholesterol in other lipoproteins was hardly or not quantified. It can be seen that cholesterol in HDL can be selectively quantified.
- HDL cholesterol in the test sample was quantified by the same method as in Example 5, except that healthy human serum was used as the test sample.
- HDL cholesterol in the same test sample was quantified by the precipitation method described in “Clinical tests”, 23, 121 (1979).
- FIG. 3 shows a correlation diagram of the obtained measurement results.
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP52647298A JP3164829B2 (ja) | 1996-12-09 | 1997-12-04 | 高密度リポ蛋白中のコレステロールの定量方法 |
EP97946102A EP0887422B1 (en) | 1996-12-09 | 1997-12-04 | Method of determining cholesterol content of high-density lipoproteins |
US09/117,806 US6479249B2 (en) | 1996-12-09 | 1997-12-04 | Method of determining cholesterol content of high-density lipoproteins |
AT97946102T ATE304608T1 (de) | 1996-12-09 | 1997-12-04 | Verfahren zur bestimmung des cholesteringehalts von high-density-lipoproteinen |
CA002246308A CA2246308C (en) | 1996-12-09 | 1997-12-04 | Method for quantifying cholesterol in high-density lipoprotein |
DE69734194T DE69734194T2 (de) | 1996-12-09 | 1997-12-04 | Verfahren zur bestimmung des cholesteringehalts von high-density-lipoproteinen |
US10/190,793 US6893832B2 (en) | 1996-12-09 | 2002-07-09 | Method for quantifying cholesterol in high density lipoprotein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP34464996 | 1996-12-09 | ||
JP8/344649 | 1996-12-09 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09117806 A-371-Of-International | 1997-12-04 | ||
US09/117,806 A-371-Of-International US6479249B2 (en) | 1996-12-09 | 1997-12-04 | Method of determining cholesterol content of high-density lipoproteins |
US10/190,793 Division US6893832B2 (en) | 1996-12-09 | 2002-07-09 | Method for quantifying cholesterol in high density lipoprotein |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998026090A1 true WO1998026090A1 (fr) | 1998-06-18 |
Family
ID=18370907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/004442 WO1998026090A1 (fr) | 1996-12-09 | 1997-12-04 | Procede pour determiner la teneur en cholesterol des lipoproteines de haute densite |
Country Status (8)
Country | Link |
---|---|
US (2) | US6479249B2 (ja) |
EP (1) | EP0887422B1 (ja) |
JP (1) | JP3164829B2 (ja) |
AT (1) | ATE304608T1 (ja) |
CA (2) | CA2637805A1 (ja) |
DE (1) | DE69734194T2 (ja) |
ES (1) | ES2248856T3 (ja) |
WO (1) | WO1998026090A1 (ja) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000057191A1 (fr) * | 1999-03-24 | 2000-09-28 | Daiichi Pure Chemicals Co., Ltd. | Procede de quantification du cholesterol |
WO2003064684A1 (fr) * | 2002-01-30 | 2003-08-07 | Denka Seiken Co., Ltd. | Procede de quantification de cholesterol dans des lipoproteines de haute densite et compositions de reactifs |
US6818414B1 (en) | 1999-06-21 | 2004-11-16 | Daiichi Pure Chemicals Co., Ltd. | Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same |
JP2005046145A (ja) * | 2003-07-17 | 2005-02-24 | Ortho Clinical Diagnostics Inc | 高比重リポタンパク質コレステロール定量化のための乾式分析要素 |
JP2005049346A (ja) * | 2003-07-17 | 2005-02-24 | Ortho Clinical Diagnostics Inc | 高比重リポタンパク質コレステロールのためのワンステップ・アッセイ |
JP2007523325A (ja) * | 2004-02-03 | 2007-08-16 | ポリマー テクノロジー システムズ インコーポレーテッド | 低密度リポプロテインからのコレステロールの室温での直接テストストリップ測定のための試薬組み合わせ、および方法 |
WO2008087895A1 (ja) * | 2007-01-15 | 2008-07-24 | Toyo Boseki Kabushiki Kaisha | 高密度リポ蛋白中コレステロール測定方法およびその試薬 |
EP2065708A1 (en) | 2007-11-28 | 2009-06-03 | Fujifilm Corporation | Method for measuring high-density lipoprotein cholesterol |
EP2108961A1 (en) | 2008-04-10 | 2009-10-14 | Fujifilm Corporation | Dry analytical element for measurement of high density lipoprotein cholesterol |
JP2011045389A (ja) * | 2001-01-31 | 2011-03-10 | Asahi Kasei Pharma Kk | 糖化蛋白質測定用組成物 |
WO2011052550A1 (ja) | 2009-10-26 | 2011-05-05 | デンカ生研株式会社 | ApoE-containing HDL中コレステロールの測定方法 |
WO2012063866A1 (ja) | 2010-11-10 | 2012-05-18 | デンカ生研株式会社 | レムナント様リポ蛋白コレステロールの定量方法及びそのためのキット |
WO2013154119A1 (ja) | 2012-04-11 | 2013-10-17 | デンカ生研株式会社 | 高密度リポ蛋白(hdl)中のコレステロール(-c)の亜分画定量方法 |
JP5534644B2 (ja) * | 2005-12-09 | 2014-07-02 | 協和メデックス株式会社 | レムナント様リポ蛋白中のコレステロール測定方法、試薬及びキット |
WO2015030236A1 (ja) | 2013-08-30 | 2015-03-05 | 積水メディカル株式会社 | 高比重リポ蛋白中のコレステロール測定方法および該方法に用いる試薬 |
JP2017060522A (ja) * | 2016-12-20 | 2017-03-30 | デンカ生研株式会社 | 高密度リポ蛋白(hdl)中のコレステロールの定量方法 |
WO2017204230A1 (ja) | 2016-05-24 | 2017-11-30 | デンカ生研株式会社 | トリグリセリドリッチリポ蛋白中のコレステロールの定量方法及び定量試薬 |
WO2019177093A1 (ja) * | 2018-03-15 | 2019-09-19 | デンカ生研株式会社 | 高密度リポ蛋白質中のコレステロールの定量方法 |
WO2019175881A1 (en) * | 2018-03-14 | 2019-09-19 | Technion Research & Development Foundation Limited | A prognostic biomarker in cancer |
WO2019189642A1 (ja) | 2018-03-28 | 2019-10-03 | デンカ生研株式会社 | リポ蛋白コレステロールの定量方法、定量試薬及び定量キット |
WO2020040238A1 (ja) | 2018-08-23 | 2020-02-27 | デンカ生研株式会社 | 非アルコール性脂肪性肝炎の検出を補助する方法 |
WO2021157631A1 (ja) | 2020-02-04 | 2021-08-12 | デンカ株式会社 | 非アルコール性脂肪肝炎の検出を補助する方法 |
WO2021246435A1 (ja) | 2020-06-02 | 2021-12-09 | デンカ株式会社 | キットおよび方法 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE400816T1 (de) * | 1999-03-01 | 2008-07-15 | Sysmex Corp | Verfahren zum austesten biologischer probenkomponenten |
CN1187609C (zh) * | 1999-11-22 | 2005-02-02 | 松下电器产业株式会社 | 胆固醇传感器和胆固醇的定量方法 |
WO2004035816A1 (ja) * | 2002-10-16 | 2004-04-29 | Kyowa Medex Co., Ltd. | 高密度リポ蛋白中のコレステロールの測定方法および試薬 |
MXPA05005708A (es) * | 2002-11-27 | 2005-07-26 | Daiichi Pure Chemicals Co Ltd | Metodo para medir lipido en lipoproteina especifica. |
CN101373190A (zh) * | 2002-11-27 | 2009-02-25 | 积水医疗株式会社 | 特定脂蛋白中的脂质测定法 |
AU2003289081B2 (en) | 2002-12-13 | 2009-11-19 | Denka Company Limited | Method of multiple quantification of cholesterol in low-density lipoproteins |
CN100564539C (zh) * | 2004-12-31 | 2009-12-02 | 浙江伊利康生物技术有限公司 | 高密度脂蛋白中胆固醇的测定试剂及制备方法 |
WO2007007392A1 (ja) | 2005-07-11 | 2007-01-18 | Wako Pure Chemical Industries, Ltd. | 新規ポリマー及びこれを用いたコレステロール測定法 |
JP5129572B2 (ja) * | 2005-09-30 | 2013-01-30 | デンカ生研株式会社 | 生体試料中の2項目の測定対象物の同時分別定量方法 |
GB0609494D0 (en) * | 2006-05-12 | 2006-06-21 | Oxford Biosensors Ltd | HDL cholesterol sensor using specific surfactant |
GB0609493D0 (en) * | 2006-05-12 | 2006-06-21 | Oxford Biosensors Ltd | Cholesterol sensor |
JP5448317B2 (ja) | 2007-09-12 | 2014-03-19 | デンカ生研株式会社 | アジ化物によるカタラーゼの阻害に起因する測定誤差の低減方法 |
JP4640400B2 (ja) * | 2007-09-28 | 2011-03-02 | 和光純薬工業株式会社 | カタラーゼ安定化剤を用いた成分測定用試薬 |
JP5925026B2 (ja) * | 2011-04-28 | 2016-05-25 | アークレイ株式会社 | クレアチニン測定用乾式試験片及びクレアチニン測定法 |
US9695464B2 (en) | 2011-11-11 | 2017-07-04 | Axis-Shield As | Blood sample assay method |
JP2013103086A (ja) | 2011-11-16 | 2013-05-30 | Mtg:Kk | 美容器 |
ES2831380T3 (es) | 2013-03-15 | 2021-06-08 | Helena Laboratories Corp | Sistema y método para evaluar cantidades o tamaños de partículas lipoproteínicas de composiciones de partículas lipoproteínicas |
JP6182008B2 (ja) * | 2013-07-24 | 2017-08-16 | デンカ生研株式会社 | 高密度リポタンパク質3中のコレステロールの定量方法及び定量試薬 |
JP7437239B2 (ja) | 2020-06-02 | 2024-02-22 | デンカ株式会社 | リポ蛋白コレステロールの定量方法およびキット |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58165800A (ja) * | 1982-03-08 | 1983-09-30 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 血清のldl−フラクシヨンのコレステリンの特異的測定法及び測定試薬 |
JPS6269999A (ja) * | 1985-09-18 | 1987-03-31 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 血清又は血漿中のhdl−コレステリンの特異的測定法及び測定試薬 |
JPS63126498A (ja) * | 1986-10-29 | 1988-05-30 | ベーリンガー・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Hdl−フラクションのコレステリンの特異的測定法及び測定試薬 |
WO1992021015A1 (en) * | 1991-05-23 | 1992-11-26 | Seman Leo J Jr | METHOD FOR DETECTING LIPOPROTEIN (a) AND ASSOCIATED CHOLESTEROL |
JPH08116996A (ja) * | 1994-10-26 | 1996-05-14 | Toyobo Co Ltd | 血清または血漿中のhdl−コレステロールを測定する方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5215886A (en) * | 1987-06-22 | 1993-06-01 | Patel P Jivan | HDL determination in whole blood |
JP2653755B2 (ja) | 1994-03-08 | 1997-09-17 | 協和メデックス株式会社 | 高密度リポ蛋白中のコレステロールの定量法 |
JP3107492B2 (ja) | 1994-04-05 | 2000-11-06 | 国際試薬株式会社 | リポ蛋白分画中の成分の定量方法 |
JP2799835B2 (ja) | 1995-01-31 | 1998-09-21 | 第一化学薬品株式会社 | コレステロールの定量方法 |
JP3614514B2 (ja) * | 1995-06-21 | 2005-01-26 | 国際試薬株式会社 | 高比重リポ蛋白分画中のコレステロールの定量方法及び定量用試薬キット |
-
1997
- 1997-12-04 AT AT97946102T patent/ATE304608T1/de not_active IP Right Cessation
- 1997-12-04 ES ES97946102T patent/ES2248856T3/es not_active Expired - Lifetime
- 1997-12-04 DE DE69734194T patent/DE69734194T2/de not_active Expired - Lifetime
- 1997-12-04 CA CA002637805A patent/CA2637805A1/en not_active Abandoned
- 1997-12-04 US US09/117,806 patent/US6479249B2/en not_active Expired - Lifetime
- 1997-12-04 EP EP97946102A patent/EP0887422B1/en not_active Expired - Lifetime
- 1997-12-04 CA CA002246308A patent/CA2246308C/en not_active Expired - Lifetime
- 1997-12-04 JP JP52647298A patent/JP3164829B2/ja not_active Expired - Lifetime
- 1997-12-04 WO PCT/JP1997/004442 patent/WO1998026090A1/ja active IP Right Grant
-
2002
- 2002-07-09 US US10/190,793 patent/US6893832B2/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58165800A (ja) * | 1982-03-08 | 1983-09-30 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 血清のldl−フラクシヨンのコレステリンの特異的測定法及び測定試薬 |
JPS6269999A (ja) * | 1985-09-18 | 1987-03-31 | ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 血清又は血漿中のhdl−コレステリンの特異的測定法及び測定試薬 |
JPS63126498A (ja) * | 1986-10-29 | 1988-05-30 | ベーリンガー・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Hdl−フラクションのコレステリンの特異的測定法及び測定試薬 |
WO1992021015A1 (en) * | 1991-05-23 | 1992-11-26 | Seman Leo J Jr | METHOD FOR DETECTING LIPOPROTEIN (a) AND ASSOCIATED CHOLESTEROL |
US5320968A (en) * | 1991-05-23 | 1994-06-14 | Seman Leo J | Method for detecting lipoprotein (a) and associated cholesterol |
JPH08116996A (ja) * | 1994-10-26 | 1996-05-14 | Toyobo Co Ltd | 血清または血漿中のhdl−コレステロールを測定する方法 |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000057191A1 (fr) * | 1999-03-24 | 2000-09-28 | Daiichi Pure Chemicals Co., Ltd. | Procede de quantification du cholesterol |
US6818414B1 (en) | 1999-06-21 | 2004-11-16 | Daiichi Pure Chemicals Co., Ltd. | Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same |
US7335483B2 (en) | 1999-06-21 | 2008-02-26 | Daiichi Pure Chemicals Co., Ltd. | Method of pretreatment of sample for quantitating cholesterol and method for quantitating cholesterol in specific lipoproteins by using the same |
JP2011045389A (ja) * | 2001-01-31 | 2011-03-10 | Asahi Kasei Pharma Kk | 糖化蛋白質測定用組成物 |
US7348158B2 (en) | 2002-01-30 | 2008-03-25 | Denka Seiken Co., Ltd. | Method of quantifying cholesterol in high density lipoprotein and reagent compositions |
WO2003064684A1 (fr) * | 2002-01-30 | 2003-08-07 | Denka Seiken Co., Ltd. | Procede de quantification de cholesterol dans des lipoproteines de haute densite et compositions de reactifs |
US8765394B2 (en) | 2002-01-30 | 2014-07-01 | Denka Seiken Co., Ltd. | Method of quantifying cholesterol in high density lipoprotein and reagent compositions |
JP2005049346A (ja) * | 2003-07-17 | 2005-02-24 | Ortho Clinical Diagnostics Inc | 高比重リポタンパク質コレステロールのためのワンステップ・アッセイ |
JP4607507B2 (ja) * | 2003-07-17 | 2011-01-05 | オルソ−クリニカル ダイアグノスティクス,インコーポレイティド | 高比重リポタンパク質コレステロールのためのワンステップ・アッセイ |
JP2005046145A (ja) * | 2003-07-17 | 2005-02-24 | Ortho Clinical Diagnostics Inc | 高比重リポタンパク質コレステロール定量化のための乾式分析要素 |
JP2007523325A (ja) * | 2004-02-03 | 2007-08-16 | ポリマー テクノロジー システムズ インコーポレーテッド | 低密度リポプロテインからのコレステロールの室温での直接テストストリップ測定のための試薬組み合わせ、および方法 |
JP5534644B2 (ja) * | 2005-12-09 | 2014-07-02 | 協和メデックス株式会社 | レムナント様リポ蛋白中のコレステロール測定方法、試薬及びキット |
WO2008087895A1 (ja) * | 2007-01-15 | 2008-07-24 | Toyo Boseki Kabushiki Kaisha | 高密度リポ蛋白中コレステロール測定方法およびその試薬 |
JP5332611B2 (ja) * | 2007-01-15 | 2013-11-06 | 東洋紡株式会社 | 高密度リポ蛋白中コレステロールの測定方法およびその試薬 |
EP2065708A1 (en) | 2007-11-28 | 2009-06-03 | Fujifilm Corporation | Method for measuring high-density lipoprotein cholesterol |
EP2108961A1 (en) | 2008-04-10 | 2009-10-14 | Fujifilm Corporation | Dry analytical element for measurement of high density lipoprotein cholesterol |
WO2011052550A1 (ja) | 2009-10-26 | 2011-05-05 | デンカ生研株式会社 | ApoE-containing HDL中コレステロールの測定方法 |
WO2012063866A1 (ja) | 2010-11-10 | 2012-05-18 | デンカ生研株式会社 | レムナント様リポ蛋白コレステロールの定量方法及びそのためのキット |
WO2013154119A1 (ja) | 2012-04-11 | 2013-10-17 | デンカ生研株式会社 | 高密度リポ蛋白(hdl)中のコレステロール(-c)の亜分画定量方法 |
US9890412B2 (en) | 2012-04-11 | 2018-02-13 | Denka Seiken Co., Ltd. | Method for quantifying subfraction of cholesterol (−C) in high-density lipoprotein (HDL) |
WO2015030236A1 (ja) | 2013-08-30 | 2015-03-05 | 積水メディカル株式会社 | 高比重リポ蛋白中のコレステロール測定方法および該方法に用いる試薬 |
WO2017204230A1 (ja) | 2016-05-24 | 2017-11-30 | デンカ生研株式会社 | トリグリセリドリッチリポ蛋白中のコレステロールの定量方法及び定量試薬 |
JP2017060522A (ja) * | 2016-12-20 | 2017-03-30 | デンカ生研株式会社 | 高密度リポ蛋白(hdl)中のコレステロールの定量方法 |
WO2019175881A1 (en) * | 2018-03-14 | 2019-09-19 | Technion Research & Development Foundation Limited | A prognostic biomarker in cancer |
WO2019177093A1 (ja) * | 2018-03-15 | 2019-09-19 | デンカ生研株式会社 | 高密度リポ蛋白質中のコレステロールの定量方法 |
WO2019189642A1 (ja) | 2018-03-28 | 2019-10-03 | デンカ生研株式会社 | リポ蛋白コレステロールの定量方法、定量試薬及び定量キット |
KR20200139154A (ko) | 2018-03-28 | 2020-12-11 | 덴카 주식회사 | 리포 단백 콜레스테롤의 정량 방법, 정량 시약, 및 정량 키트 |
WO2020040238A1 (ja) | 2018-08-23 | 2020-02-27 | デンカ生研株式会社 | 非アルコール性脂肪性肝炎の検出を補助する方法 |
WO2021157631A1 (ja) | 2020-02-04 | 2021-08-12 | デンカ株式会社 | 非アルコール性脂肪肝炎の検出を補助する方法 |
WO2021246435A1 (ja) | 2020-06-02 | 2021-12-09 | デンカ株式会社 | キットおよび方法 |
Also Published As
Publication number | Publication date |
---|---|
ATE304608T1 (de) | 2005-09-15 |
CA2246308C (en) | 2008-11-18 |
CA2246308A1 (en) | 1998-06-18 |
DE69734194T2 (de) | 2006-06-29 |
ES2248856T3 (es) | 2006-03-16 |
US20020001819A1 (en) | 2002-01-03 |
JP3164829B2 (ja) | 2001-05-14 |
DE69734194D1 (de) | 2005-10-20 |
CA2637805A1 (en) | 1998-06-18 |
EP0887422A1 (en) | 1998-12-30 |
EP0887422A4 (en) | 2002-10-23 |
US6479249B2 (en) | 2002-11-12 |
EP0887422B1 (en) | 2005-09-14 |
US20020192732A1 (en) | 2002-12-19 |
US6893832B2 (en) | 2005-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998026090A1 (fr) | Procede pour determiner la teneur en cholesterol des lipoproteines de haute densite | |
AU735659B2 (en) | Method for quantifying cholesterol present in low density lipoprotein | |
JP2600065B2 (ja) | 高密度リポ蛋白中のコレステロールの定量法 | |
US8785146B2 (en) | Method for quantitative measurements of HDL-C and LDL-C | |
JPH07301636A (ja) | 高密度リポ蛋白中のコレステロールの定量法 | |
US8765394B2 (en) | Method of quantifying cholesterol in high density lipoprotein and reagent compositions | |
JP3058602B2 (ja) | 低密度リポ蛋白中のコレステロールの定量方法 | |
CA2337559C (en) | Method and reagent for determination of cholesterol in remnant-like particles | |
EP2639310B1 (en) | Method for quantification of remnant-like lipoprotein cholesterol and kit for same | |
JP3288033B2 (ja) | 高密度リポ蛋白中のコレステロール定量用試薬 | |
JP3644490B2 (ja) | 高密度リポ蛋白中のコレステロールの定量方法 | |
JP4059586B2 (ja) | 低密度リポ蛋白中のコレステロールの定量方法 | |
JP4519239B2 (ja) | 低密度リポ蛋白中のコレステロールの定量方法 | |
KR100540086B1 (ko) | 저밀도 리포단백질 중의 콜레스테롤 정량방법 | |
JP4865880B2 (ja) | 低密度リポ蛋白中のコレステロールの定量方法 | |
MXPA99009358A (en) | Method for quantitating cholesterol present in low density lipoproteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09117806 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2246308 Country of ref document: CA Ref country code: CA Ref document number: 2246308 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997946102 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1997946102 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997946102 Country of ref document: EP |